Malignant melanoma is an aggressive form of skin cancer that is generally fatal if untreated. Approximately 10-20% of patients treated with ipilimumab may experience significant long term survival benefits. However, a UK agency recently recommended against public funding for ipilimumab on the grounds that no biomarkers have been discovered to identify the small group of […]
Read More